355142-36-8

Usage

Uses

Used in Pharmaceutical Industry:
ASISCHEM R44416 is used as a pharmaceutical intermediate for its role in the synthesis of various medicinal compounds. Its chemical properties make it a valuable component in developing new drugs and improving existing pharmaceutical formulations.
Used in Organic Synthesis:
In the field of organic synthesis, ASISCHEM R44416 serves as a reagent, contributing to the creation of a wide array of organic compounds. Its versatility in chemical reactions is essential for advancing research and innovation in organic chemistry.
Safety and Storage:
When handling ASISCHEM R44416, it is crucial to take safety precautions to prevent skin and eye irritation. Additionally, proper storage conditions, such as keeping the compound in a cool, dry place away from heat and light sources, are necessary to ensure its stability and effectiveness in its applications.

InChI:InChI=1/C12H7ClO4/c13-10-3-1-7(5-9(10)12(15)16)11-4-2-8(6-14)17-11/h1-6H,(H,15,16)

Upstream product

• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 913835-32-2 3-carboxy-4-chlorophenylboronic acid 
• 98-01-1 furfural 
• 89-54-3 2-chloro-5-aminobenzoic acid 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 64401-55-4 5-amino-2-chloro-benzoic acid ethyl ester 
• 752231-43-9 ethyl 2-chloro-5-(5-formylfuran-2-yl)benzoate 

Downstream Products

• 292065-64-6 5-(5-((1-(3-carboxyphenyl)-3-methyl-5-oxo-1,5-dihydro-4Hpyrazol-4-ylidene)methyl)furan-2-yl)-2-chlorobenzoic acid 
• 745039-52-5 C₂₃H₁₅ClN₂O₆ 
• 312706-42-6 C₂₂H₁₅ClN₂O₄ 
• 292640-64-3 C₁₅H₈ClNO₄S₂ 
• 330996-24-2 C₁₆H₉ClN₂O₅S 
• 752231-43-9 ethyl 2-chloro-5-(5-formylfuran-2-yl)benzoate 

Relevant academic research and scientific papers

XPA INHIBITOR COMPOUNDS AND THEIR USE

The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.

Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction

XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.

KU INHIBITORS AND THEIR USE

The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.

FURANE DERIVATIVES AS INHIBITORS OF ATAD2

The invention relates to fur an e derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.

Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors

We previously identified two small molecules targeting the HIV-1 gp41, N-(4-carboxy-3-hydroxy)phenyl-2,5-dimethylpyrrole 12 (NB-2) and N-(3-carboxy-4-chloro)phenylpyrrole 13 (NB-64), that inhibit HIV-1 infection at low micromolar levels. On the basis of m

Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors

A novel compound inhibiting HIV-1 integrase has been identified by means of virtual screening techniques. A small family of structurally related molecules has been synthesized and biologically evaluated with some of the compounds possessing micromolar act

Discovery of new Gram-negative antivirulence drugs: Structure and properties of novel E. coli WaaC inhibitors

Heptosyltransferases such as WaaC represent promising and attractive targets for the discovery of new Gram-negative antibacterial drugs based on antivirulence mechanisms. We report herein our approach to the identification of the first micromolar inhibitors of WaaC and the preliminary SAR generated from this family of 2-aryl-5-methyl-4-(5-aryl-furan-2-yl-methylene)-2,4-dihydro-pyrazol-3-on es identified by virtual screening.

Oxadiazolopyrazine derivatives as pharmaceutically active compounds

The present invention relates to furazanopyrazine derivatives of the general formula (I): wherein:R' represents -NR1R2 or -OR9R" represents -NR5-NR3R4, -NR5-ORb, -O-NR